Mineralys Therapeutics (MLYS) Assets Average (2023 - 2026)
Mineralys Therapeutics (MLYS) posted Assets Average of $657.3 million for Q1 2026, up 4.19% sequentially from $630.9 million in Q4 2025, and up 134.41% YoY from $280.4 million in Q1 2025.
Mineralys Therapeutics (MLYS) Assets Average (2023 - 2026) Analysis & Trends
Mineralys Therapeutics has reported Assets Average for 4 years, with the latest figure at $657.3 million in Q1 2026.
- Quarterly Assets Average rose 134.41% year-over-year to $657.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $657.3 million (up 134.41% YoY) and the FY2025 annual result came in at $433.9 million, up 89.65% from the prior year.
- Assets Average rose to $657.3 million in Q1 2026 per MLYS's latest filing, from $630.9 million in the prior quarter.
- Over five years, Assets Average peaked at $657.3 million in Q1 2026 and troughed at $210.4 million in Q1 2023.
- A 4-year average of $354.1 million and a median of $298.8 million in 2023 frame the typical range for Assets Average.
- The sharpest annual moves came in 2024 and 2025: Assets Average fell 10.4% in 2024, then surged 166.11% in 2025.
- Over 4 years, Assets Average stood at $264.6 million in 2023, then fell by 10.4% to $237.1 million in 2024, then soared by 166.11% to $630.9 million in 2025, then climbed by 4.19% to $657.3 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $657.3 million, $630.9 million, and $467.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Mineralys Therapeutics | 2.27 Bn | 1.60 Bn | - | 660.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 660.36 Mn |
| Mar 31, 2026 | 657.33 Mn |
| Dec 31, 2025 | 630.88 Mn |
| Sep 30, 2025 | 467.84 Mn |
| Jun 30, 2025 | 345.33 Mn |
| Mar 31, 2025 | 280.42 Mn |
| Dec 31, 2024 | 237.08 Mn |
| Sep 30, 2024 | 293.37 Mn |
| Jun 30, 2024 | 332.87 Mn |
| Mar 31, 2024 | 299.44 Mn |
| Dec 31, 2023 | 264.60 Mn |
| Sep 30, 2023 | 284.39 Mn |
| Jun 30, 2023 | 298.83 Mn |
| Mar 31, 2023 | 210.44 Mn |